Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ENO1 | P06733 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28706167 | 0.98 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL30893638 | 0.88 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL30893637 | 0.86 | ENO1 (0.47) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL30893639 | 0.86 | ENO1 (0.47) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL5709535 | 0.86 | ENO1 (0.47) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL12207994 | 0.84 | ENO1 (0.50) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL868257 | 0.82 | ENO1 (0.56) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL27002702 | 0.82 | ENO1 (0.49) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL10917702 | 0.82 | ENO1 (0.49) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 | |
| SCHEMBL12597725 | 0.81 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1ENO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086242-B1 | 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-L H-IMIDAZOLE AND ITS PHARMACEUTICAL USE | RIVUS PHARMACEUTICALS INC (US) | 2026-04-08 | — | — | EP | claimed |
| CN-121570433-A | Glutamine metabolism regulation nano drug delivery system for enhancing pancreatic cancer targeting and penetration, and preparation method and application thereof | 复旦大学 | 2026-02-27 | — | — | CN | claimed |
| US-20240425462-A1 | Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-12-26 | — | — | US | claimed |
| CN-116803989-A | Preparation process of 1-N-methyl-2-nitro-5-hydroxymethyl imidazole | 深圳艾欣达伟医药科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116583303-B | Tripterine conjugates and uses thereof | 瑞阳公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4086242-B1 | 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-L H-IMIDAZOLE AND ITS PHARMACEUTICAL USE | RIVUS PHARMACEUTICALS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-121570433-A | Glutamine metabolism regulation nano drug delivery system for enhancing pancreatic cancer targeting and penetration, and preparation method and application thereof | 复旦大学 | 2026-02-27 | — | — | CN | disclosed |
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250214944-A1 | Novel Phenyl Derivatives | Rivus Pharmaceuticals, Inc. | 2025-07-03 | — | — | US | disclosed |
| WO-2025056913-A1 | COMPOUND AND METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-20 | — | — | WO | disclosed |
| US-20250011348-A1 | Synthesis Process of X-IPM, Stable Crystal Form and Application Thereof | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2025-01-09 | — | — | US | disclosed |
| US-20240425462-A1 | Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
| EP-0081719-B1 | 2-NITRO-IMIDAZOLS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-04-23 | — | — | EP | disclosed |
| US-4515790-A | Antiprotozoal 2-nitroimidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0081719-A2 | 2-Nitro-imidazols | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-06-22 | — | — | EP | disclosed |
| US-3987053-A | ANTIMICROBIAL | GRUPPO LEPETIT S.P.A. (IT) | 1976-10-19 | — | — | US | disclosed |
| US-3954789-A | 2-Nitroimidazole derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011348-A1 | Synthesis Process of X-IPM, Stable Crystal Form and Application Thereof | CHRM2, CHRM1, INMT | ALDH1A1 4493/4885SMN1; SMN2 4169/4885KDM4E 546/4885 |
| US-20240425462-A1 | Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole | DNMT1, COX4I1, NDC1 | ALDH1A1 788/4885SMN1; SMN2 895/4885KDM4E 612/4885 |
| US-20250214944-A1 | Novel Phenyl Derivatives | TFAM, GOT2, NDUFAB1 | ALDH1A1 1313/4885SMN1; SMN2 1309/4885KDM4E 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.